Work

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

Year: 2015
Type: letter
Abstract: We thank Pietrantonio et al , for their interest in our recent manuscript ( Rowland et al, 2015 ). We also acknowledge their mutual interest in the field, and share their goal of informing clinicians with the most accurate and complete evidence to ensure that patients with metastatic colorectal cancer (mCRC) are both afforded access and guided to the most appropriate treatment interventions.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W1727309928
Cites: 37
Cited by: 229
Related to: 10